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relevance for patients with chronic hepatitis C
Coffee intake has been reported to exert a number of beneﬁcial
effects on health including among others, reducing the risk of
type 2 diabetes, reducing inﬂammatory activity and C reactive
protein in various diseases and diminishing oxidative stress.
The ﬁrst observations regarding potential beneﬁcial effects of cof-
fee consumption on alanine aminotransferase and c-glutamtyl
transferase activities in patients with chronic liver disease
(CLD) were already reported in the 1990s [1,2]. Since then, evi-
dence for this association gained signiﬁcant support in several
studies performed in Japan, Europe and the US. Recently Freed-
man and co-workers have conducted a large prospective study
in 766 participants of the HALT-C study who had chronic hepati-
tis C (CHC) with bridging ﬁbrosis and cirrhosis and who failed to
achieve a sustained virologic response to pegylated interferon
and ribavirin [3]. In this study coffee consumption at base line
was shown to be associated with a number of factors including
less severe steatosis and lower alanine aminotransferase levels.
Furthermore, regular coffee consumption during the observation
period (median follow-up 3.8 years) was associated with lower
rates of disease progression. In this study, association of coffee
intake with progression of liver disease was independent of alco-
hol intake and cigarette smoking. One year later, Modi and co-
workers reported that caffeine consumption, mainly from regular
coffee, at an equivalent of 2–3 cups a day, was associated with
less severe ﬁbrosis on liver biopsies, as observed in a cohort of
177 patients, of whom 68% had CHC [4]. Finally, two recent
meta-analyses conﬁrmed the protective effect of coffee intake
on the development of hepatocellular carcinoma in patients with
cirrhosis [5,6].
In the present issue of the Journal, Costentin and co-workers
assessed the impact of caffeine consumption on necroinﬂammato-
ry disease activity and grade of ﬁbrosis in a relatively homogenous
cohort of 238 treatment naïve patients with histologically proven
CHC, predominantly with genotype 1. Caffeine intake was estab-
lished as the sum of mean consumption of coffee, tea and caffeine
containing beverages and categorized into four levels according to
the calculated daily dose. Multivariate analysis revealed that daily
caffeineconsumptionof408 mgwasassociatedwitha lesser riskof
necro-inﬂammatory activity as determined by the Metavir score.
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and ﬁbrosis stage. The results in the present study conﬁrm a num-
ber of previous observations that caffeine intake has an indirect or
direct effect on suppression of necroinﬂammtory activity as
assessed by ALT measurements or by a liver biopsy in CLD in gen-
eral and in CHC in particular. However, it stands in contrast to a
number of previous studies including the recent report of Modi
et al. who found a beneﬁcial effect of caffeine on progression of
ﬁbrosis in CHC and most probably in CLD of other etiologies. How
can these conﬂicting observations be reconciled? Costentin and
co-workers try to provide a hypothesis to explain this difference
which suggests that suppression of necroinﬂammatory liver injury
by caffeine directly or indirectly slows down the progression of
ﬁbrosis. Although this may be the case, such a hypothesis does
not provide a clue to decipher themechanism involved in the hep-
ato-protective effect(s) of coffee and caffeine in CLD. In their study,
Modi et al. could not establish a link between coffee consumption
and hepatic inﬂammation and suggest that caffeine may have an
independent anti-ﬁbrogenic effect in the liver, possibly through
inhibition of the transforming growth factor b pathway [4]. The
impact of such a putative anti-ﬁbrotic effect was not observed in
the present study by Costentin et al. Last but not least, in addition
to caffeine, coffee contains hundreds of other compounds which
may act in concert with caffeine in suppressing the necro-inﬂam-
matory activity in patients with CHC and CLD. The lack of a control
group of CHC patients consuming decaffeinated coffee in the pres-
ent study does not enable assessment of the speciﬁc hepato-
protective effect of caffeine on such activity.
In conclusion, many previous reports as well as the report dis-
cussed herewith, suggest that coffee consumption has a beneﬁ-
cial effect on disease progression in CHC and possibly also in
CLD of other etiologies as reviewed in the articles by Freedman
and Modi et al. [3,4]. Thus, irrespective of the controversy regard-
ing the mechanism involved and regardless of other potential
confounding factors such as alcohol consumption and/or ciga-
rette smoking, the already available evidence suggests that 2–3
cups of coffee a day are beneﬁcial in patients with chronic liver
disease in general and in CHC patients with advanced ﬁbrosis
in particular.The overlap between hepatitis A and HIV: European patients
with acute hepatitis A should be tested for HIV
The hepatitis A virus (HAV) is transmitted mainly through the
fecal-oral route, spreading primarily through close personal
contact. Household and sexual contact with another person with11 vol. 54 j 1085–1086
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hepatitis A has been among the most frequently identiﬁed risks
in the Western hemisphere. In 2007, this type of contact
accounted for 8% of reported cases in the US [7]. Outbreaks of
hepatitis A among injection-drug users and men who have sex
with men (MSM) who are known to be at an increased risk for
HIV infection continue to occur [8–10]. HAV patients with HIV
co-infection develop protracted hepatitis A viremia with slow
clinical resolution as compared to non-HIV patients with normal
CD4 cell counts [11–13]. Testing for hepatitis A in patients
belonging to these risk groups who present with clinical signs
of hepatitis is by now common practice. In contrast, routine test-
ing for HIV among patients with serologically proven acute hep-
atitis A is far less common.
In the present issue of the Journal, Girardi and co-workers
present their retrospective analysis on the prevalence of HIV
infection among 473 reported Italian patients (77% males) tested
in Rome at the National Institute for Infectious Diseases between
2002 and 2008. Results of serologic tests for HIV were available
for 203/368 male and 15/105 female patients. Only 39% of the
203 males reported same gender sex activities in a questionnaire
designed to identify risk factors. Overall HIV prevalence was
15.2% in 56/368 male patients with acute hepatitis A. This ﬁgure
rose to 27.6% for the 203 patients with available test results. Only
1/15 females with acute hepatitis A tested positive for HIV (6.7%).
Most importantly, 13/56 HIV positive male patients were una-
ware of their HIV status until tested positive for both acute
HAV and HIV infection. Moreover, 2/13 HIV positive patients with
acute hepatitis A, were still in the phase of recent primary acute
HIV infection. Since only 50% of sera of all patients were avail-
able for HIV testing, these data on the prevalence of HIV in this
speciﬁc cohort, most probably, are underestimated.
The results of this survey deliver a clear message for clinicians
as well as public health ofﬁcials: in the absence of clearly identi-
ﬁable risk factors such as travel to HAV endemic areas, patients
presenting with acute hepatitis in countries with low or very
low endemic hepatitis A should also be offered HIV testing.
Finally, an obvious consequence of the available information sug-
gests that MEM who are at increased risk for contracting HAV
infection should be immunized against hepatitis A.1086 Journal of Hepatology 2011Conﬂict of interest
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